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AbstrACt
Introduction The economic cost of osteoarthritis (OA) is 
high. At least 4.4 million people have hand OA in the UK. 
Symptomatic thumb base OA affects 20% of people over 
55 years, causing more pain, work and functional disability 
than OA elsewhere in the hand. Most evidence-based 
guidelines recommend splinting for hand OA. Splints that 
support or immobilise the thumb base are routinely used 
despite there being limited evidence on their effectiveness. 
The potential effects of placebo interventions in OA are 
acknowledged, but few studies investigate the clinical 
efficacy of rehabilitation interventions nor the impact of 
any placebo effects associated with splints.
Methods and analysis Participants aged 30 years and 
over with symptomatic thumb base OA will be recruited 
into the trial from secondary care occupational therapy 
and physiotherapy centres. Following informed consent, 
participants will complete a baseline questionnaire and 
then be randomised into one of three treatment arms: 
a self-management programme, a self-management 
programme plus a verum thumb splint or a self-
management programme plus a placebo thumb splint. The 
primary outcome is the Australian Canadian Osteoarthritis 
Hand Index (AUSCAN) hand pain scale. The study endpoint 
is 8 weeks after baseline. Baseline assessments will be 
carried out prior to randomisation and outcomes collected 
at 4, 8 and 12 weeks. Cost-effectiveness analysis will be 
conducted and individual qualitative interviews conducted 
with up to 40 participants after 8 weeks to explore 
perceptions and outcome expectations of verum and 
placebo splints and exercise.
Ethics and dissemination South Central—Oxford C 
Research Ethics Committee approved this study (16/
SC/0188). The findings will be disseminated to health 
professional conferences, journals and lay publications 
for patient organisations. The research will contribute to 
improving the management of thumb base OA and help 
clinicians and patients make informed decisions about the 
value of different interventions.
trial registration number ISRCTN 54744256.
IntroduCtIon
Osteoarthritis (OA) is a leading cause 
of pain, disability, healthcare utilisation 
and productivity loss in the UK. Each year 
approximately two million adults visit their 
general practitioner (GP) with symptoms of 
OA.1 OA is more prevalent in women, the 
incidence increases with age and recent 
estimates suggest more than 150 million 
strengths and limitations
 ► This trial is powered to evaluate the clinical bene-
fit and statistical significance of adding splinting 
to a self-management programme for people with 
thumb base osteoarthritis (OA).
 ► This is the first trial to use a placebo thumb splint in-
tervention and will add to the understanding of con-
textual aspects of such visible physical treatment 
and self-management programmes for OA.
 ► The trial has been informed and designed with the 
input of patients and expert clinicians and the trial 
outcome measures have been agreed as meaningful 
by patients.
 ► The 12-week trial follow-up period is limited and 
longer term follow-up would provide further useful 
outcome data.  on O
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Europeans have radiographic hand OA and 15 million 
have symptomatic arthritis.2 Symptomatic thumb base 
(first carpometacarpal and/or scaphotrapezial joint) 
OA affects approximately 22% of people aged 50 years 
and over.3 Thumb base OA is likely to become more 
prevalent in the future since the incidence increases 
with age4 and is identified as a priority for treatment 
as it causes more pain and disability and is associated 
with a worse prognosis than other hand sites affected 
by OA.5
Patients with thumb base OA present with predomi-
nantly mechanical usage-related pain over the thumb 
base6 and are more likely to have more pain, work 
disability and reduction in quality of life and function, 
and to receive more anti-inflammatory drugs and more 
splinting than participants with OA affecting other hand 
joints5 7–9
Thumb base OA affects entire hand function10 and 
the overall impact, particularly in older people, can be 
substantial, with many experiencing difficulties with daily 
household, caring, work and leisure activities.11 Despite 
the scale of this problem, it appears that both patients 
and practitioners often believe that there is little that can 
be done.12
Therapeutic splinting for thumb base OA aims to mini-
mise or eliminate motion at the thumb carpometacarpal 
joint (CMCJ)13 in order to prevent joint deterioration 
and/or deformity, decrease pain and increase overall 
hand function.14 The process of designing thumb splints 
currently lacks detailed reporting but biomechanical 
principles have been applied to one design to off-load the 
dynamic forces occurring during functional hand use on 
a symptomatic CMCJ.15 It is known that stabilisation of 
the CMCJ to reduce pain levels impacts on hand func-
tionality.16 Currently, thumb splints are recommended 
for patients with thumb base OA.17 However, the efficacy 
of splinting based on this approach has not yet been 
established and forms the rationale for this trial. Some 
evidence based on small, non-powered samples18 19 show 
thumb splints can help relieve pain; however, evidence 
to support their effectiveness is not yet fully supported 
by robust research.20 There is insufficient evidence to 
suggest that the combination of splinting delivered along-
side hand exercises is more effective than hand exercises 
alone21–23 and the evidence to support splinting in alle-
viating hand pain in the medium term is supported by 
low-level evidence only.24 To date, there has also been no 
examination of any contextual and non-specific patient–
practitioner interaction effects associated with splinting 
in thumb base OA. If this is substantial, optimising the 
non-specific effects of treatment could improve treatment 
effectiveness and overall care of people with OA in a safe 
and cost-effective way.25 26 This randomised controlled 
trial (RCT) protocol was designed in accordance with the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials checklist,27 to evaluate the effectiveness, 
efficacy and cost-effectiveness of thumb splints for people 
with thumb base OA.
The primary objective of this trial is to determine the 
clinical effectiveness and efficacy of thumb splints when 
added to a self-management programme for people with 
symptomatic thumb base OA. The trial questions:
1. Is there a benefit of adding a thumb base splint to a 
self-management programme for people with thumb 
base OA?
2. Is there a difference in benefit between adding a ver-
um or a placebo thumb base splint to a self-manage-
ment programme for people with thumb base OA?
3. What are patients’ views and experiences of the ef-
fectiveness, acceptability and adherence to the trial 
interventions?
MEthods And AnAlysIs
Patient and public involvement
Exploring the effectiveness of orthotic devices for use by 
patients living with OA was identified as a priority area 
for investigation by an Arthritis Research UK patient 
stakeholder committee. Two patient and public group 
meetings were carried out with eight patient partners 
living with hand OA to listen to patient experiences of 
living with hand OA, explore intervention components 
of the trial and help to inform co-design a placebo 
splint design.28 Patient partners discussed with the team 
what splints they thought should be included in a trial, 
which splint designs they found most credible and which 
outcomes were important to them. These discussions 
informed the study design. A national Delphi study with 
therapy clinicians and patients was conducted, to inform 
and agree trial processes.29 30 Clinicians tended to want 
more focused time efficient measures where patients 
usually hoped for more comprehensive intervention that 
was beyond the time allocated to National Health Service 
(NHS) outpatient provision. This helped to consider treat-
ment burden from both clinical and patient’s view points. 
This involvement at an early stage ensured that clinicians 
felt that they had contributed and had ownership in 
the trial design and patient input ensured that patients’ 
perspectives had been integral to the study design hope-
fully making the trial relevant and appealing to prospec-
tive patients. We conducted a focus group to explore the 
support required by NHS therapy clinicians when know-
ingly delivering placebo splints.31 A pilot study across five 
NHS recruitment sites to test recruitment and proce-
dural feasibility and safety and the convincing delivery 
of a newly designed placebo splint was conducted and 
reported.32 The education and support needs identified 
by therapy clinicians taking part in a placebo controlled 
RCT was sought and recorded.33 This informed the trial 
training for clinicians. Our patient partner and co-author 
(CHG) provided a patient’s perspective in developing 
recruitment strategies, study conduct and lay dissemina-
tion routes.
trial design and setting
The Osteoarthritis Thumb Therapy (OTTER) II Trial is 
a pragmatic, multi-centred, single (participant) blind, 
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Table 1 OTTER II Trial patient inclusion and exclusion criteria
Inclusion criteria
1 Aged 30 years and over
2 At least moderate hand pain (AUSCAN42 hand pain score >5) and moderate functional hand disability (AUSCAN42 
hand functional disability score >9)
3 Show signs and symptoms of thumb base OA on clinical enquiry and examination, specifically: hard tissue 
enlargement of the first CMCJ OR squaring of the thumb base OR pain that worsens when pinching OR pain that 
worsens on span grip (eg, opening a jar) OR crepitus on movement OR reduction in thumb base range of movement 
OR positive thumb adduction provocation test52 OR positive thumb extension provocation test52 OR pain on 
palpation of the dorso-radial aspect of the thumb CMCJ
4 No other household member participating in the trial
5 Able to give written informed consent
6 Available to attend occupational therapy/physiotherapy/hand therapy sessions
Exclusion criteria
1 Consultation with therapy department or treatment for this thumb problem (excluding pain killers and anti-
inflammatories) in the previous 6 months
2 Intra-articular joint injection to wrist, fingers or thumb in the previous 2 months
3 Fractures or significant injury or surgery to the wrist or hand within the previous 6 months
4 Red flags. History of serious illness or disease such as any other diagnosed rheumatic conditions: gout, psoriatic 
arthritis, ankylosing spondylitis, connective tissue disorders (systemic lupus, systemic sclerosis), resulting in 
inflammatory arthritis in the hand/s, or, progressive neurological signs, or acute swollen hand joint
5 Diagnosis of dementia or other significant disorder likely to affect communication
6 Already received thumb splints for thumb base OA
7 Skin disease that may interfere or contraindicate splint wear
8 Participant of a drug or medical device trial in the last 12 weeks
CMCJ, carpometacarpal joint; OA, osteoarthritis; OTTER Trial, Osteoarthritis of the Thumb Therapy Trial.
superiority randomised controlled clinical effectiveness 
and efficacy trial. People with symptomatic thumb base 
OA reporting moderate to severe thumb base pain, will be 
equally allocated to one of three groups: Group A: 8 weeks 
of a facilitated self-management programme, Group B: 8 
weeks of a facilitated self-management programme plus a 
verum splint or Group C: 8 weeks of a facilitated self-man-
agement programme plus a placebo splint. All groups will 
be encouraged to continue their self-management and, 
where appropriate, splint wear until follow-up at 12 weeks 
from baseline. The study will run from 28th February 
2017 to 14th March 2019.
Participants will be recruited consecutively from refer-
rals to occupational therapy or physiotherapy (Therapy) 
departments from new, current and review patients of 
Rheumatology, Orthopaedic, Hand Surgery Units and 
General Practice at 17 NHS recruitment sites (online 
supplementary appendix 1). Intervention will be delivered 
by a qualified OTTER II Trial trained occupational ther-
apist or physiotherapist who has worked independently 
in a clinical role treating patients with hand OA and who 
works within a therapy department that accepts referrals 
for patients with thumb base OA.
Participants
Participant inclusion criteria were decided on iteratively 
with our rheumatologists, clinicians and hand surgeons in 
relation to the literature about prevalence, incidence rates 
and current treatment by therapy departments in the UK. 
Clinical tests, that contributed to inclusion criteria, were 
selected following: review of literature; consideration of 
the sensitivity and specificity of each test; examination of 
the practicality and feasibility of the testing procedure for 
the collaborating clinicians working across different UK 
hospitals. As there is no clear consensus on the longevity 
of the impact of intra-articular steroid injections into 
the first CMCJ,34–36 we used local clinical NHS protocols 
relating to the length of time suggested to repeat first 
CMCJ steroid injections, to inform our inclusion criteria.
Consecutive potential participants will be screened and 
assessed for recruitment into the trial by the collaborating 
the OTTER II Trial trained therapy clinicians using inclu-
sion and exclusion criteria as shown in table 1. The char-
acteristics of participants who fulfil inclusion criteria and 
who decline to take part will be recorded.
Interventions
The trial’s three intervention arms all include 90 min 
of direct therapy intervention delivered by a qualified 
OTTER II Trial trained occupational therapist or phys-
iotherapist who has worked independently in a clinical 
role treating patients with hand OA and who works within 
a therapy department that accepts referrals for patients 
with thumb base OA.
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The direct therapy intervention will be delivered in a 
60 min baseline appointment at an NHS secondary care 
hospital or clinic, when the interventions listed below will 
be delivered. A 30 min follow-up intervention at week 4 
will be conducted, where progress is reviewed and any 
necessary adjustments made. A final third hospital visit 
at week 8 is for finalisation of trial procedures only and 
includes no direct therapy intervention.
The three intervention arms, delivered at the baseline 
appointment are:
Group A: optimal self-management programme
The self-management programme (online supplemen-
tary appendix 2) includes:
1. Teaching standardised hand exercises (developed 
from an evidence-based review37) and provision of a 
trial-specific hand exercise booklet.
2. Provision of a trial-specific booklet about joint protec-
tion, activity pacing and general advice about OA fol-
lowed by a discussion with the therapist of the content.
3. Provision of the Arthritis Research UK Osteoarthritis 
information booklet.
4. A discussion with the therapist of the facilitators and 
barriers to engaging with self-management principles.
5. A patient hand exercise diary.
Group B: optimal self-management programme plus a verum 
thumb base splint
Group B participants receive:
1. The optimal self-management programme as detailed 
above in Group A.
2. A verum splint. Therapists and participants will be giv-
en an option of two different splints, with the choice 
guided by a standardised Splint Decision Protocol (on-
line supplementary appendix 3).
The splinting options informed by the study’s design 
and development stage will be:
 ► Procool Thumb CMC Restriction splint (black) (Ref 
PTRS).
Or
 ► Orfilight 2.5 mm 3/32" microperforated (beige) 
trouser leg splint (custom made by the therapist from 
a pre-cut standardised trial template and standardised 
strapping protocol). 
Both splints will be delivered with instructions on 
how to wear and use the splint (online supplementary 
appendix 4). The Procool thumb CMC restriction splint 
comes in packaging with a label providing details of the 
manufacturer and washing instructions.
3. A discussion with the therapist of the facilitators and 
barriers to engaging with splint wear (online supplemen-
tary appendix 5).
4. A patient splint wear diary (online supplementary 
appendix 6).
Group C: optimal self-management programme plus a placebo 
thumb base splint
Group C participants receive:
1. The self-management programme as detailed above in 
Group A.
2. A placebo splint. There will be the choice of two de-
signs of placebo splint. These are made in a lightweight 
nylon, secured around the wrist and have phalangeal 
components but no basal thumb joint support. One is 
black and the other is beige to match the verum splint 
options and three sizes will be manufactured. They 
have been designed with no known active compo-
nent and none was detectable during testing.38 A stan-
dardised Splint Decision Protocol about which splint 
will be most appropriate to issue in which situation will 
be used (online supplementary appendix 7). The pla-
cebo splints arrive in packaging with a label providing 
details of the manufacturer, washing instructions and 
a lifestyle education leaflet about how to position and 
wear the splint. Both splints will be delivered with in-
structions on how to wear and use the splint.
3. An information sheet to outline when the splint should 
be worn (online supplementary appendix 4)
4. A discussion with the therapist of the facilitators and 
barriers to engaging with splint wear (online supple-
mentary appendix 5).
5. A patient splint wear diary (online supplementary ap-
pendix 6)
Trained OTTER II Trial clinicians will deliver a stand-
ardised self-management package of care using their clin-
ical judgement to apply the content for each individual 
patient. Participants in group A will receive more time 
spent on self-management than participants in groups B 
and C.
Concomitant care
Any relevant contralateral thumb treatment for partici-
pants will be delayed until the end of the trial. There will 
be no alteration in participants’ general concomitant care 
while on the trial. Additional treatments, for example, 
joint injection, surgery and reported purchase or use of 
own splints during the study period will be captured on 
self-report questionnaires. Criteria for modifying allo-
cated interventions are detailed within the OTTER II 
Trial Safety Information.
Investigator training
Trial training visits will be conducted by the OTTER II 
Trial management team (JA, PB and PW) to carry out 
standardised instruction and demonstration for OTTER 
II Trial research clinicians prior to the start of patient 
recruitment. Training will cover procedures for main-
taining clinical assessor and participant blinding, delivery 
of eligibility tests, interventions, reporting of safety events, 
data entry and use of case report forms (CRFs). Sites will 
also be visited by the trial team (JA, MW and CM) to 
provide support and guidance on maximising participant 
recruitment through liaison with surgery and community 
health teams, and to conduct quality assurance evalua-
tions of intervention delivery as required.
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A page of the trial website which is only available to site 
staff (not participants or the public) will provide training 
videos on the standardised delivery of all the trial interven-
tions. All clinicians will complete the National Institute of 
Health Research Good Clinical Practice (GCP) training 
in order to have the skills and knowledge necessary to 
comply with the international ethical, scientific and prac-
tical standards to which all clinical research is conducted. 
Compliance with GCP provides public assurance that the 
rights, safety and well-being of research participants are 
protected and that research data are reliable.39
Participant identification and baseline assessment
Potential participants will receive a letter about the study 
and a participant information sheet (PIS) at the hospital 
clinic or by post. For interested patients an outpatient 
therapy department appointment will be made at week 0 
(baseline). Following eligibility screening, formal written 
consent will be obtained and participants will complete 
the baseline assessments. Consent will be obtained by an 
NHS therapist trained in OTTER II Trial procedures.
randomisation
Eligible patients will be enrolled into the study via the 
Oxford Clinical Trials Research Unit (OCTRU) online 
randomisation service and this system will record eligi-
bility and stratification data.
When participants are randomised to a treatment 
arm, this constitutes the date of start of treatment. 
Participants will only be randomised once and for the 
treatment of one thumb. For participants with symp-
toms of bilateral thumb base OA, the most painful 
thumb will be treated first within the trial. If at the end 
of the trial participants require treatment on a contra-
lateral thumb, then participants will be invited back by 
the clinical service to undergo routine (ie, non-trial) 
clinical intervention.
Randomisation will be on a 1:1:1 basis. The first 30 
participants will be randomised using a simple random 
list with varying block sizes to seed the subsequent mini-
misation algorithm. This random list is generated by the 
trial statistician and concealed from all other members 
of the trial team to ensure future treatment allocations 
cannot be predicted. Subsequent participants will be 
randomised using a validated computer randomisa-
tion programme (Registration / Randomisation and 
Management of Product (RRAMP)) with a minimisation 
algorithm, which will ensure balanced treatment alloca-
tions across the stratification factors (centre, baseline 
AUSCAN hand pain score (Category 1=AUSCAN pain 
scores 6–12 and Category 2=AUSCAN hand pain scores 
13–20) and treated hand dominance). The minimisa-
tion system includes a random element (0.8) to mini-
mise predictability of treatment allocations for new 
participants.
Participants will be blind to treatment allocation. 
Strategies to maximise participant blinding include 
training for trial clinicians in how to present and discuss 
the treatment arms positively without disclosing other 
treatment options and routine assessment included in 
the quality assurance trial monitoring visits of clini-
cian’s communication and interaction in presenting 
treatment options with participants. The PIS has 
been carefully worded to state that an element of the 
self-management intervention may be placebo but 
does not state what aspect this may be. The study will 
be described as a comparison of self-management 
interventions and not divulging detail about placebo 
splinting in any clinician communication. Trial partici-
pants will not receive group intervention and therefore 
cannot compare their interventions received and we 
will not include participants who have already received 
thumb base splints. All of these strategies will help to 
maintain participant blinding. Contamination between 
treatment arms will be limited by identifying on hospital 
notes that the patient is part of the OTTER II Trial and 
therefore should not receive any further hand therapy 
treatment from the hospital team. It is not possible to 
prevent participants allocated to arm A or C purchasing 
their own splints during the trial period; however, the 
data will be captured in the final study questionnaire 
and will be used to assess any degree of contamination. 
The OTTER II Trial placebo splints will not be able to 
purchased privately.
This approach will support participant blinding, in 
addition to the training that treating therapists will 
receive about delivering placebos and responding 
to participant questions. The success of participant 
blinding will be assessed via patient questionnaires at 
12 weeks.
treatment and follow-up
Figure 1 flowchart shows the participants’ progress 
through the trial. After randomisation, participants 
will receive their allocated intervention during a 
60 min appointment (week 0). All participants in each 
treatment arm will receive a 10 min telephone call at 
2 weeks from the therapist to check for adherence to 
the self-management programme and to discuss any 
problems identified by the participant as relevant. In 
addition for Groups B and C participants, the therapist 
will check splint wear and comfort. Participants will 
attend for a 30 min appointment 4 weeks after rando-
misation, to review treatments and make adjustments 
where necessary and an assessor blind to treatment 
allocation will administer the objective Grip Ability 
Test40. A final hospital visit occurs 8 weeks after rando-
misation. A paper questionnaire will be posted to each 
participant at 12 weeks to collect follow-up patient-re-
ported outcomes. After the 12-week follow-up has been 
completed (study endpoint), all patients will be offered 
the option of a further follow-up appointment for any 
further care that is needed. If patients have received 
verum splints, then they may keep these, if patients have 
received placebo splints or self-management alone then 
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Figure 1 Participants’ process throughout the trial. NHS, National Health Service; OT, occupational therapy; OTTER II Trial, 
Osteoarthritis Thumb Therapy II Trial.
they will be offered the opportunity to receive a verum 
splint if required.
Qualitative interviews
Between weeks 8 and 12, a qualitative telephone inter-
view will take place for a subgroup of patients in inter-
vention arms B and C. The researcher will be blinded 
for the qualitative interviews to prevent bias related to 
treatment allocation during data collection. In order 
to make this practical, the researcher carrying out data 
collection will be independent from the RCT and will 
be unfamiliar with the splints and differences between 
them. The methodological approach for the qualitative 
study will be a framework analysis. Purposive sampling 
will be used and based on male to female ratio (as per 
the study sample); age and AUSCAN hand pain index 
at baseline. Interviews will be conducted with up to 40 
participants. Interviews will be semistructured, using a 
topic guide informed by patient partners, to elicit expe-
rience of splint and self-management interventions, 
splint preference, adherence and views about reasons 
for effectiveness. There will be a password for each 
participant that has agreed to take part in the inter-
view study so that the participant can be correctly iden-
tified on the telephone. Consent for participation in 
the qualitative interview will be sought and given at the 
time of entry into the main study.
The schedule of enrolment, interventions and a 
summary of assessments are shown in table 2. Detailed 
information about baseline assessments and outcome 
measures are listed in table 3.
The Global Assessment of Change41 question adapted 
for the OTTER II study asks ‘With respect to your 
thumb base pain how would you describe yourself now 
as compared with the start of your OTTER Trial therapy 
treatment’. The answer is given on a five-point Likert 
scale, that ranges from ‘very much worse’, ‘worse’, over 
‘no change’ to ‘better’ and ‘completely recovered’. The 
AUSCAN hand index for pain42 recorded at baseline 
and 8 weeks is the primary outcome measure. The CRFs 
for this study can be obtained from the first author (JA)
sample size
The sample size has been calculated based on under-
taking a global analysis of covariance (ANCOVA) for 
the primary outcome, AUSCAN hand pain42 at 8 weeks, 
adjusting for the baseline pain score and stratification 
factors (including centre and treated hand dominance) 
across all three treatment arms using the power and 
sample size package, PASS 11 (PASS 11. NCSS, LLC. 
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Table 2 Schedule of enrolment, interventions and assessments
Time point:
Study period
Enrolment Allocation Post-allocation Close-out
Baseline
day 0 Baseline day 0 2 weeks 4 weeks 8 weeks
9–11 
weeks 12 weeks
After 12 
weeks
Enrolment:
  Eligibility screen* X
  Informed consent* X
  Randomisation/allocation X
Interventions:
  Optimal NHS self-management 
care
X
  Optimal NHS self-management 
care plus verum splint
X
  Optimal NHS self-management 
care plus placebo splint
X
  Telephone call check of progress X
  Review of self-management care 
and splint wear (if applicable)
X
Assessments:
  Baseline assessments: see 
table 3
X
  Outcomes: Grip Ability Test40 X X
  Outcomes: see table 3 X
  Outcomes at follow-up: See 
table 3
X
  Exercise adherence   
  Splint adherence   
  Qualitative interviews (selected 
participants)
X
  Patient request for further 
treatment
X
*The eligibility screen and informed consent can optionally be carried out prior to time point 0.
NHS, National Health Service.
Kaysville, Utah, USA. www. ncss. com). Assuming 80% 
power, a 5% two-sided significance in order to detect a 
standardised mean difference of 0.4 (a moderate effect 
size43 based on a difference in the AUSCAN hand pain 
score of 2 points) and assuming a SD of 5, based on data 
from the OTTER pilot study,31 requires 92 participants 
per arm. Allowing a 20% loss to follow-up at 8 weeks 
inflates this to 115 participants per arm, giving a total of 
345 participants.
The sample size has taken into account the global 
comparison of the null hypothesis that there is no 
difference between the three treatment arms, and pair-
wise comparisons will only be undertaken if this global 
comparison is statistically significant. No further adjust-
ment for the sample size has been undertaken to allow 
for multiple testing.
Clustering is not a consideration in sample size as 
‘Centre’ is a stratification factor, and although there 
may be more than one therapist per centre, this 
should largely ensure balance across treatment arms 
within each centre. The Data and Safety Monitoring 
Committee (DSMC) (online supplementary appendix 
8) will review the assumptions underlying this sample 
size calculation after approximately 50% of the partici-
pants have been recruited and followed up for 8 weeks, 
if still within the recruiting period.
recruitment strategy
Recruitment targets and procedures have been tested 
in the pilot study32 and are based on these data. Recruit-
ment start dates for the collaborating sites will be stag-
gered over a 6-month period.
data collection, management and analysis
The trial will use a series of CRFs to record trial activities 
and RCT site staff will ensure that each CRF is completed 
properly and stored in the investigator’s site file (ISF). 
Site staff will make photocopies and post CRFs to the 
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Table 3 Baseline assessment and outcome measures
Measure Screening Baseline 4 weeks 8 weeks 12 weeks
Work Productivity and Activity Impairment Questionnaire)48 ✓ ✓ ✓
Generic Quality of Life (SF12-V2)53 ✓ ✓ ✓
EuroQol 5 Dimensions 5-Levels questionnaire46 ✓ ✓ ✓
AUSCAN hand stiffness42 ✓ ✓ ✓
Michigan Hand Questionnaire54 ✓ ✓ ✓
Thumb pain over the last week ✓ ✓ ✓
Disability of the arm, shoulder, hand questionnaire55
Leisure section only
✓ ✓ ✓
Arthritis Self-Efficacy Pain Scale56 ✓ ✓ ✓
AUSCAN hand pain42 ✓ ✓ ✓
AUSCAN hand function42 ✓ ✓ ✓
Global assessment of change41 ✓ ✓
Health utilisation questionnaire ✓ ✓
The objective clinician assessed Grip Ability Test40 ✓ ✓ ✓
OTTER Trial team using freepost envelopes, according 
to a standard operating procedure (SOP) so that both 
sites and the trial centre will have a copy of CRFs.
Participants will complete questionnaires at base-
line, 8 weeks and 12 weeks. Participants will be asked 
to record the frequency for which hand exercises were 
completed for at least 20 min using a daily diary. Splint 
wear diaries will be used to capture hours per day of 
splint wear and will contribute to per protocol analysis 
of data. Participants will be provided with freepost enve-
lopes in order to return questionnaires and diaries to 
the trial centre.
Where postal follow-up questionnaires are not 
received when expected, first they will be chased by 
post, and if there is no response key endpoint data will 
be collected over the phone. Up to three phone calls 
will be made to obtain key endpoint data. If participants 
wish to withdraw from their randomised intervention, 
they will still be included in the trial follow-up, unless 
they request to be excluded from follow-up. Where 
available, reasons for withdrawal from follow-up will be 
collected.
The OTTER Research Team will make copies of 
CRFs, questionnaires and diaries created by or received 
directly at the trial centre and post them to the relevant 
site to be filed in the ISF. The original documents will 
be secured in the Trial Master File.
Eligibility and stratification data will be entered 
directly onto the OCTRU online randomisation system 
by site staff. All other data will be entered into the trial 
database by the OTTER Research Team. The OTTER 
Trial team will check each CRF for completeness and 
where appropriate contact the site for missing data. 
A data management and sharing plan contains fully 
comprehensive information about all aspects of data 
management. All data will be processed according to 
the Data Protection Act 2018. All study-specific docu-
ments, except for the signed consent form and letters to 
participants, will refer to the participant with a unique 
study participant number/code and not by name.
Quantitative data will be stored on an OpenCli-
nica trial-specific database prepared and managed by 
OCTRU. Qualitative data will be stored in QRS NVivo 
and word documents. The database has inbuilt data 
validation checks and a trial management system for 
managing data queries. Peer review of data entry will 
be conducted on 5% of CRFs. Data discrepancies will 
be reviewed on a regular basis to help clean the data. 
All data will be securely stored only accessible by autho-
rised personnel agreed by the Principal Investigator, 
Legal services at the University of Southampton and 
The OTTER II Trial Steering Committee. Data will be 
backed up, and participant identifiable data will be 
stored separately from study data. Trial documenta-
tion will be retained for 10 years after completion of 
study-related activities and managed in accordance with 
the University of Southampton and the University of 
Oxford research data management policies.
Audio-recordings from the interviews will be tran-
scribed verbatim, and participants allocated an ID 
number. The text of the interviewer notes from the 
telephone interviews will be anonymised and linked to 
the interview through the ID number. Names of partic-
ipants, the names of any people discussed, healthcare 
employees and hospitals will be removed from tran-
scripts and replaced with pseudonymns. Participants 
will be sent a letter to thank them for taking part in the 
telephone interview. A ‘future use of interview’ ques-
tion is included on the consent form which gives copy-
right to the Universities of Southampton and Oxford to 
use the material in research, teaching, publications and 
broadcasting.
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statistical analysis
The statistical analysis will be carried out by the OTTER 
II Trial OCTRU trial statistician. As is usual practice for 
the Oxford Cinical Trials Unit the statistician will not be 
blind to treatment allocation. There are rigourous checks 
and balances in place to ensure that the trial statistician 
cannot bias outcome.
This three-arm trial will first assess the global compar-
ison of differences between the three treatment arms at 
the 5% level. The primary (global) null hypothesis is that 
there is no difference between the three arms. Only if this 
null hypothesis is rejected at the 5% (two-sided) signifi-
cance level, will the pairwise comparisons be carried out 
in order to explore where the difference lies:
 ► Verum splint +self-management programme (Group 
B) versus self-management programme alone (Group 
A)
 ► Placebo splint +self-management programme (Group 
C) versus self-management programme alone (Group 
A)
 ► Verum splint +self-management programme 
(Group B) versus placebo splint +self-management 
programme (Group C)
It is anticipated that there will be an adjustment for 
multiple testing at this stage, and Bonferroni or a less 
conservative method will be used. The main analysis 
will be intention to treat. A per-protocol analysis of the 
primary endpoint will be performed as part of the sensi-
tivity analyses. A statistical analysis plan will provide full 
details of all planned analyses.
The statistical analysis of the primary outcome, 
AUSCAN hand pain score, will be performed using 
ANCOVA, adjusting for baseline pain and stratification 
factors. Continuous secondary outcomes will be anal-
ysed using similar methods to the primary outcome. The 
unadjusted secondary binary variables will be compared 
using χ2 tests with logistic regression being used to adjust 
for stratification and important prognostic factors in a 
multi-variable framework.
Baseline characteristics for the three groups will be 
presented using the appropriate descriptive statistics. 
Baseline characteristics of participants who completed 
the trial and those who dropped out will be presented 
and explored in order to ascertain patterns of loss to 
follow-up. Subgroups will be examined to look for consis-
tency of any observed treatment effects (using interac-
tions). This analysis will be considered of an exploratory 
nature potentially providing hypotheses for future studies. 
The study is not powered to examine these in detail and 
will not therefore report p values for these.
Qualitative analysis
In all, 40 interviews will be carried out by a researcher 
blind to participant treatment allocation.
Audio-recordings of the 40 interviews will be tran-
scribed verbatim, anonymised and imported into anal-
ysis software QRS NVivo. The researcher will conduct 
primary coding of the narrative data and the five stages of 
framework analysis as described by Ritchie and Lewis44 will 
be followed: familiarisation, identifying a thematic frame-
work, indexing, charting and mapping/ interpretation.
Using a thematic approach,45 data will be inductively 
coded, codes grouped to create categories and a descrip-
tive account will be produced. Up to 10 interviews will 
be double coded to increase the validity of the findings. 
Double coding means more than one researcher inde-
pendently assigning pre-specified codes to the qualita-
tive data. NVivo software (QSR International) will be 
used to facilitate the double coding process. This allows 
for coding comparisons to be run between different 
coders. The results are returned according to the 
kappa coefficient score and the percentage of agree-
ment between coders. After double coding transcripts, 
we plan to use this coding comparison for discussion 
and reflection on the data. The numeric measure will 
be used as a method of comparison to gauge if there 
is agreement and understanding of the definitions of 
the codes between team members. Any discrepancies 
identified will then be discussed until an agreement is 
reached and any differences resolved. The account will 
provide structured descriptions of participants’ experi-
ence of self-management and splints, including reasons 
for their views about effectiveness as well as information 
about acceptability and adherence.
Quality of life analysis
The EuroQol 5 Dimensions 5-Levels (EQ-5D-5L) ques-
tionnaire46 will be administered to participants at base-
line, 8 weeks and 12 weeks. Responses will be converted 
into utilities using tariffs estimated from a representative 
sample of the UK population.47 Survival information 
collected from the trial will be combined with EQ-5D util-
ities to generate Quality Adjusted Life-Years (QALYs).
Economic evaluation and analysis
The perspective adopted in the economic analysis will 
be that of the NHS. Costs associated with the following 
healthcare resource categories over the 8-week inter-
vention period and follow-up period (12 weeks) will be 
included.
 ► Intervention provision (including splints and clinical 
staff time required for splinting); and
 ► Primary care contacts, including surgery and home 
visits by GPs, nurses, and out-of-hours medical services, 
and community therapists; and
 ► Hospital care services, including scheduled and 
unscheduled inpatient admissions, surgery, accident 
and emergency visits and outpatient care contacts.
Primary and hospital care resource use will be obtained 
from patient questionnaires administered at 8 weeks and 
at 12-week follow-up. Healthcare resources will be valued 
using unit cost schedules such as Personal Social Services 
Research Unit and NHS Reference costs. Costs associated 
with splints and other disposables will be obtained from 
the manufacturers and the NHS Supply Chain catalogue. 
Using the Work Productivity and Activity Impairment 
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Questionnaire,48 the number of work days lost by study 
participants and the impact that OA had on the levels of 
productivity/activity and unpaid work will also be meas-
ured over both study periods.
An economic evaluation adherent to guidelines for 
good economic evaluation practice49 will be undertaken. 
A within-trial cost-utility analysis will explore the incre-
mental cost per QALY gained by splinting of the thumb 
base and a self-management programme when compared 
with (1) placebo-splinting and a self-management 
programme and (2) a self-management programme 
alone. The analyses will be conducted at 8 weeks and at 12 
weeks. Cost and effect results will be reported as means 
with SD, with mean differences between the two patient 
groups reported alongside 95% CIs. Depending on the 
amount of missing cost and quality of life data, missing 
data will be imputed using recommended multiple impu-
tation methods,50 with results from this analysis being 
presented as an additional sensitivity analysis.
Incremental cost-effectiveness will be calculated by 
dividing the difference in costs by the difference in effects. 
Uncertainty around the incremental cost-effectiveness 
ratio will be explored using non-parametric bootstrap-
ping. A supplementary economic evaluation including 
non-NHS costs will be conducted in an additional sensi-
tivity analysis. This will include costs of impaired produc-
tivity/activity and, any work and non-work days (eg, 
leisure or non-paid work) lost due to illness will be valued 
using mean average wages for those in employment. For 
participants who are retired or those not in employment, 
loss in activity levels (eg, leisure, caring or non-paid work 
activities) due to illness will be valued using minimum 
wages.
EthICs And dIssEMInAtIon
The quality assurance evaluation of trial processes and 
intervention fidelity using a trial monitoring template 
will be carried out on 50% of the recruiting sites by 
the research team. Should there be no noted issues no 
follow-up monitoring will be conducted. There are no 
criteria that will flag a need to initiate a quality evaluation; 
however, continual scrutiny of the CRFs received from sites 
by the study team will alert the research team to possible 
issues (eg, incomplete completion of CRFs, missing data 
or mis-randomisation) that may subsequently require 
quality assurance evaluation. A standard risk assessment 
will be conducted and a risk-based proportionate moni-
toring plan will be put in place, which will include central 
monitoring.
Adverse event and safety oversight will comply with 
OCTRU SOPs. Adverse responses/reactions, adverse 
device effects, serious adverse responses/reactions, 
serious adverse device effects, suspected unexpected 
serious adverse responses/reactions (SUSARs) and device 
deficiencies will be recorded as study outcomes. Sites will 
be required to report all serious events that are related to 
a trial intervention within 24 hours and all related serious 
adverse events must be assessed for causality and reason 
for seriousness. All device deficiencies, adverse reactions 
and adverse device effects must be reported to the trial 
team within 14 days. All serious adverse event safety moni-
toring forms will be passed on to the Trial’s Nominated 
Clinician who will perform an independent assessment 
of causality and will also perform assessment of expected-
ness based on what is known and documented about the 
intervention/device. Any SUSARs will be reported to the 
Research Ethics Committee within 15 days of the Trials 
Office being made aware of the event.
An independent DSMC (online supplementary 
appendix 8) will be convened with two expert clinicians 
and a statistician to regularly review accumulating data in 
order to assess patient safety and study conduct following 
the recommendations of the DAMOCLES study51 with 
full details being provided in a charter. They will advise 
the Trial Steering Committee (online supplementary 
appendix 9) as to whether recruitment should stop early, 
which is only likely to occur if either intervention is shown 
to be unsafe for patients. As this is a low-risk study, no 
interim efficacy comparative analyses are planned and no 
safety issues are expected. The OTTER II Trial team will 
have access to the final trial dataset and there will be no 
public access to patient level data or the statistical code 
used within the trial.
We believe this to be the first fully powered placebo 
controlled splinting trial exploring the effectiveness 
and efficacy of splints in symptomatic thumb base OA. 
Study results will be disseminated to rheumatology, 
hand therapy, occupational therapy and physiotherapy 
national and international conferences and submitted 
for consideration in international and national academic 
and professional conferences and journals. Lay publica-
tions written in accessible language will be provided to 
charitable, community and patient facing publications 
as recommended by our patient and public involvement 
partners. Study participants will be provided regular 
updates of the study progress through the OTTER II 
study website.
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